Hypertriglyceridemia (hyperTG) is a common characteristic of endotoxemia. At high doses of endotoxin, hyperTG is caused by a reduction in the activity of lipoprotein lipase (LPL), the enzyme responsible for TG intravascular clearance. The present studies were aimed at evaluating the role of nitric oxide (NO), overproduced in endotoxemia through the activation of inducible NO synthase (iNOS), in the decrease in tissue LPL activity brought about by lipopolysaccharide (LPS, 15 mg/kg). In rats, the specific iNOS inhibitor aminoguanidine (AGN, 100 mg/kg) prevented the LPS-induced threefold elevation in plasma TG concentration, through actions that were not related to changes in hepatic TG secretion. AGN administration abrogated the LPSinduced reduction in LPL activity in skeletal muscle but not that in white adipose tissue (WAT). Quantification of LPL mRNA revealed that AGN prevented LPS-mediated alterations in muscle LPL activity through posttranscriptional mechanisms. The above findings were confirmed in iNOS (-/-) knockout mice injected with endotoxin. LPS increased plasma TG concentration in wild-type mice by 75%, whereas hyperTG did not occur in knockout mice. Skeletal muscle LPL activity decreased by 40% in wild-type mice but remained unchanged in knockout mice 6 h after LPS injection, whereas WAT LPL activity decreased to one-third of control levels in both genotypes. These findings demonstrate that, after LPS administration, reduced muscle LPL activity and the resulting hyperTG are caused by the overproduction of NO via the induction of iNOS. The findings further provide evidence for a central role of muscle LPL in the response of TG metabolism to acute endotoxemia.
. It has been shown that whereas low doses of endotoxin mostly affect the former process (8) , the hypertriglyceridemia seen after high doses of endotoxin is in large part caused by the decreased activity of lipoprotein lipase (LPL; EC 3.1.1.34), the rate-limiting enzyme responsible for the intravascular hydrolysis of TG [reviewed in ref. 9 ].
During short-term endotoxemia, LPL is down-modulated by as-yet-unknown posttranscriptional mechanisms in both adipose tissue and skeletal muscle (10) , which are two major sites of LPL production. Modulation of LPL at or upstream of the mRNA level appears to become involved only after longer periods of endotoxin or cytokine exposure (6, 11, 12) . No evidence is yet available concerning the downstream mediators of the effects of endotoxin on LPL in various tissues.
Endotoxin administration in rodents stimulates the expression and activity of inducible nitric oxide synthase (iNOS) in adipose tissue (13) as well as in skeletal muscle (14) (15) (16) (17) ) from 4 h after endotoxin exposure to at least 8 h, which leads to overproduction of nitric oxide (NO) in these tissues. Among other targets, activation of iNOS and overproduction of NO notably interfere with insulin-stimulated glucose uptake in skeletal muscle (14, 15) . It has recently been demonstrated that NO also mediates the tumor necrosis factor .71)-.-induced reduction in LPL in cultured brown adipocytes (18, 19) . However, these in vitro studies evaluated the effects of only one cytokine after prolonged periods of exposure (24 h), which is not necessarily representative of the endotoxin-mediated, short-term LPL reduction in skeletal muscle and adipose tissue in vivo.
Therefore, the aims of the present studies were to determine the contribution of iNOS and NO in the acute (6 h) decrease in adipose and muscle LPL activity brought about by a high dose of endotoxin, and to evaluate its impact on hypertriglyceridemia. To this end, lipopolysaccharide (LPS) was injected in rats pretreated with aminoguanidine (AGN), a relatively specific iNOS inhibitor, to test whether iNOS blockade could blunt or prevent the LPS-induced reduction in LPL and the appearance of hypertriglyceridemia. Hepatic TG secretion rate was also assessed to evaluate the implication of the liver in the elevation in plasma TG caused by LPS administration. Another cohort of rats treated with LPS was subjected to a euglycemic-hyperinsulinemic clamp to assess the possible role of insulin, a major modulator of LPL (20) , in endotoxemia-induced alterations in enzyme activity. Finally, iNOS knockout (-/-) mice were used to assess further in a genetic model the contribution of iNOS to the LPS-induced reduction in LPL and hypertriglyceridemia.
MATERIALS AND METHODS

Study 1: Pharmacolocical inhibition of iNOS
Male Sprague-Dawley rats (group of 12) initially weighing 250-275 g were purchased from Charles River Laboratories (St. Constant, Canada) and were housed individually in stainless steel cages in a room kept at 23 ± 1Û&ZLWKDKOLJKW-dark cycle (lights on at 7:00). The animals were cared for and handled in conformance with the Canadian Guide for the Care and Use of Laboratory Animals, and the protocols were approved by our institutional animal care committee. Rats initially had ad libitum access to tap water and nonpurified chow (Rodent chow #5075, Ralston Products, Woodstock, Ontario, Canada). One week after their arrival, rats were divided randomly into four groups according to a 2 × 2 factorial design. Food was removed from cages until the end of the following protocol. Half of the rats received saline (1 ml/kg, i.p.), and the other half were given aminoguanidine (AGN, 100 mg/kg; Sigma, St-Louis, MO) dissolved in saline. It was determined in preliminary studies that this dose of AGN does not completely inhibit iNOS-mediated NO production but that it avoids interaction with the other NOS subtypes noted with higher doses of AGN. After 30 min, the endotoxin lipopolysaccharide (LPS, from Escherichia coli, serotype 055:B5, 15 mg/kg; Sigma) was injected i.p. to half of these groups, whereas the remaining half received saline. A previous study (21) and our preliminary experiments have determined that the 30-min delay between AGN and LPS administration was sufficient to attain the full effect of AGN. Rats were killed by decapitation 6 h later, and blood and tissues were harvested and treated as described below. The experiment was repeated once, and both protocols yielded similar results.
Triglyceride secretion rate
A cohort of 20 male Wistar rats was used for assessment of TG secretion rate. One week after their arrival, rats were fitted with a permanent polyethylene cannula in the left jugular vein under isoflurane anesthesia and were allowed to recover from surgery for three days. On the day of the experiment, rats were injected with AGN and LPS exactly as indicated above. After 5.5 h, a solution of Triton WR 1339 (300 mg/ml, Sigma) was injected through the cannula (1 ml/kg) such that the midpoint of the time curve coincided with the time of killing in the other studies. Because the animals had not eaten for at least 6 h, TG secretion can be considered to be largely of hepatic origin. Plasma TG levels were quantitated in serial blood samples taken through the venous catheter before and 20, 40, and 60 min after the administration of Triton. TG secretion rate was calculated by multiplying the slope of the regression line of plasma TG concentration vs. time by plasma volume estimated from body weight and was expressed as PROPLQ
Hyperinsulinemic clamp in rats treated with LPS
Male Sprague-Dawley rats (200-250 g) purchased from Charles River were housed in individual cages under the conditions described above. Under ketamine/xylazine anesthesia (80 mg/kg and 10 mg/kg, respectively), rats were fitted with a permanent polyethylene cannula in the left jugular vein and another permanent polyethylene cannula in the right carotid artery. Three days after cannulation, overnight-fasted rats were weighed and transferred to a quiet isolated room. Once installed, rats were allowed to acclimatize to their new surroundings for 60 min. We collected a first blood sample via the carotid artery catheter for basal levels of glucose and insulin. All animals were then injected with LPS (15 mg/kg, i.p.). The clamp was performed essentially as described by Kraegen et al. (22) . Insulin dissolved in a solution of 0.9% NaCl containing 0.1% albumin (Fraction V, fatty acid-free, Sigma) was infused at a rate of 64 mU/kg body weight/min into the jugular vein. Every 5 min, 20 µl of blood was taken from the carotid artery to measure glycemia. A 25% glucose solution dissolved in 0.9% NaCl was infused into the jugular vein from the beginning of the clamp and was adjusted thereafter to maintain glycemia near the basal level. Sham infusions were similarly performed, except that no insulin was present in the NaCl/albumin solution and that no glucose was infused. After 5 h, the animals were killed with an overdose of the ketamine/xylazine solution described above, and the gastrocnemius muscle, epididymal, and perirenal white adipose tissues were harvested in addition to blood.
Study 2: genetic invalidation of iNOS
A group of 26 wild-type and 26 iNOS knockout mice (genetic background: C57BL/6J × 129/SvJ, kindly provided by C. Nathan, New York, NY), kept under pathogen-free conditions and housed at 23Û&ZLWKDKOLJKW-dark cycle, were injected, after food removal, with LPS (20 mg/kg) or saline (n=13 in each group) and were killed 6 h later. Blood was collected by cardiac puncture, and tissues were harvested and treated as described below. A pilot study showed that LPL of male and female mice responded similarly, and that analyses were thus performed with values pooled for gender.
Plasma and tissue sampling
Immediately after killing, blood was collected and centrifuged (1,500 g, 15 min at 4Û&DQGWKH separated plasma was stored at -70Û& XQWLO ODWHU ELRFKHPLFDO PHDVXUHPHQWV 3HULUHQDO DQG epididymal white adipose tissues (WAT) and gastrocnemius, soleus, tibialis, and vastus lateralis skeletal muscles were excised, and ~50 mg of each tissue was homogenized with all-glass tissue grinders (Kontes, Vineland, NJ). Adipose tissue samples were homogenized in 1 ml of a solution containing 0.25 mol/l sucrose, 1 mmol/l EDTA, 10 mmol/l Tris-HCl, and 12 mmol/l deoxycholate, pH 7.4. Muscle samples were homogenized in 1 ml of a solution containing 1 mol/l ethylene glycol, 50 mmol/l Tris-HCl, 3 mmol/l deoxycholate, 10 IU/ml heparin, and 5% (v/v) aprotinin (Trasylol, Miles Pharmaceuticals, Rexdale, Canada), pH 7.4. Muscle homogenates were frozen quickly at -70Û& $GLSRVH WLVVXH KRPRJHQDWHV ZHUH FHQWULIXJHG (12,000 g, 20 min at 4Û&DQGWKHIUDFWLRQEHWZHHQWKHXSSHUIDWOD\HUDQGWKHERWWRPVHGLPHQW was removed, diluted with 4 volumes of the homogenization solution without deoxycholate, and stored at -70Û& Xntil lipoprotein lipase activity measurement. Lipoprotein lipase in tissue homogenates represents a pool of endothelium-bound and active intracellular enzyme. The response of this total pool to various physiological conditions generally parallels that of the heparin-releasable, endothelium-bound fraction, although not necessarily to an identical extent (23) .
RNA extraction and RT-PCR
Total cellular RNA from epididymal WAT and gastrocnemius muscle was isolated by using guanidium thiocyanate-phenol-chloroform extraction with the TRIzol Reagent (Life Technologies) based on the method developed by Chomczynski and Sacchi (24) . cDNA synthesis and amplification were performed exactly as previously described (15) . Sequences of the antisense and sense oligonucleotides (based on rat LPL and GAPDH) were as follows; LPL: 5'-CCAGCAGCATGGGCTCCAAG-3' and 5'-GAAGACACAGCTGAGGACAC-3', GAPDH: 5'-AGATCCACAACGGATACATT -3' and 5'-TCCCTCAAGATTGTCAGCAA-3'. The expected sizes of the amplification products were 358 base pairs for LPL and 331 base pairs for GAPDH. The amplification products were run in 8% acrylamide gels and stained with ethidium bromide, and fluorescence associated with DNA bands was analyzed by laser scanning densitometry and quantitated with the NIH Image software.
Plasma determinations
We measured plasma glucose concentrations by using the glucose oxidase method with the Beckman glucose analyzer. Insulin was determined by RIA by using a reagent kit from Linco Research (St. Charles, MO) with rat insulin as standard. Plasma TG were measured by an enzymatic method using a reagent kit from Boehringer Mannheim (Montréal, Canada), which allowed correction for free glycerol. Plasma nonesterified fatty acids (NEFA) were also determined by an enzymatic colorimetric technique (Wako Pure Chemical Industries, Richmond, VA). Corticosterone concentrations were measured by RIA (ICN Pharmaceuticals Inc, Orangeburg, NY). Nitric oxide concentration was evaluated by the accumulation of its stable degradation products nitrite and nitrate (25) . Deproteinized plasma samples were incubated with nitrate reductase (0.1 U/ml) in the presence of 50 µmol/l NADPH and 5 µmol/l FAD for 15 min at 37Û&WRUHGXFHQLWUDWHWRQLWULWH Samples were then incubated for 5 min at 37Û&ZLWKODFWDWH dehydrogenase (10 U/ml) and sodium pyruvate (10 mmol/l) to oxidize the remaining NADPH. We then measured total nitrite by using the Griess reagent (1.0% sulfanilamide/0.1% N- [1- naphthyl]-ethylenediamine dihydrochloride), and the absorption was read at 540 nm.
Tissue LPL activity
Thawed tissue homogenates (100 µl) were incubated under gentle agitation for 1 h at 28Û&ZLWK 100 µl of a substrate mixture consisting of 0.2 mol/l Tris-HCl buffer, pH 8.6, which contained 10 MBq/l [carboxyl-14 C]triolein (Amersham, Oakville, Canada) and 2.52 mmol/l cold triolein emulsified in 50 g/l gum arabic, as well as 20 g/l fatty acid-free bovine serum albumin, 10% human serum as a source of apolipoprotein C-II, and either 0.2 or 2 mol/l NaCl. Free oleate released by LPL was then separated from intact triolein and mixed with Universol (NEN, Montréal, Canada), and sample radioactivity was determined in a scintillation counter. LPL activity was calculated by subtracting lipolytic activity determined in a final NaCl concentration of 1 mol/l (non-LPL activity) from total lipolytic activity measured in a final NaCl concentration of 0.1 mol/l. LPL activity was expressed as microunits (1 µU = 1 µmol nonesterified fatty acids released per hour of incubation at 28Û&7KHLQWHUDVVD\FRHIILFLHQWRIYDULDWLRQZDVDQG was determined by using bovine skim milk as a standard source of LPL. Protein content of the tissue extracts was measured by the method of Lowry et al. (26) . Data are expressed as specific activity of LPL (µU/g tissue protein).
Statistical analysis
Data are presented as means ± SE. Group means were compared by using a 2 × 2 factorial analysis of variance (ANOVA) to determine main effects of LPS and aminoguanidine (or genotype) and their interactions. Differences between individual group means were analyzed by Fisher's protected least-squares difference (PLSD) test. Differences were considered statistically significant at P < 0.05.
RESULTS
Study 1: pharmacological inhibition of iNOS
Plasma TG concentration was close to threefold higher in LPS-treated rats (3.5 vs. 1.2 mmol/l) than in control animals (Fig. 1A) . Whereas AGN had no effect by itself, the iNOS inhibitor completely blunted the LPS-induced hypertriglyceridemia (LPS-AGN interaction: P<0.0002).
LPS administration in rats lowered plasma glucose (P=0.002) and insulin (P=0.007) levels (Table 1 ) and increased plasma NEFA and corticosterone concentrations. Plasma NO 3 /NO 2 levels were greatly elevated (4.5-fold compared with controls, P<0.0001) 6 h after LPS injection. AGN alone had no effect on either glycemia, insulinemia, plasma NO 3 /NO 2 , or corticosterone levels, whereas it slightly but significantly increased plasma NEFA concentrations. The LPSinduced increase in plasma NO 3 /NO 2 was reduced significantly (-50%) by previous AGN treatment (LPS-AGN interaction: P<0.0001).
LPS treatment induced iNOS protein levels by approximately four-to fivefold in both skeletal muscle and WAT (data not shown). LPS decreased LPL specific activity by at least 50% in the gastrocnemius muscle and epididymal WAT ( Fig. 1B; both P<0.0001) . The effect of LPS on LPL activity was also observed in other muscles and adipose depots, including the soleus, tibialis, and vastus lateralis muscles, and perirenal WAT (not shown). In the gastrocnemius muscle, AGN administration completely prevented the LPS-induced decrease in LPL activity (LPS-AGN interaction: P<0.05), whereas in epididymal WAT, AGN did not affect LPL activity in either saline-or LPS-injected rats (Fig. 1B) . LPL mRNA (adjusted for that of GAPDH mRNA) was not significantly affected by either LPS or AGN in both skeletal muscle and WAT (Fig. 1C) .
Triglyceride secretion rate was measured after administration of Triton 1339, which blocks intravascular TG clearance. LPS not only failed to increase TG secretion but rather diminished TG secretion by 50% (from 5.5 to 2.8 µmol/min, P<0.05), whereas TG secretion was not affected by AGN alone (Fig. 2) . However, AGN injection before LPS administration dampened the LPS-induced reduction in TG secretion. Therefore, LPS-induced hypertriglyceridemia was not due to an increase in TG output into the circulation. Rather, LPS-induced hypertriglyceridemia was due entirely to reduced TG clearance, as further illustrated by the fact that Triton administration (inhibition of clearance) to control animals resulted in similar final plasma TG levels compared with those obtained after LPS injection.
To verify whether the LPS-induced decrease in plasma insulin contributed to the LPS-induced decrease in WAT LPL or partially counteracted that of muscle LPL, LPS-treated rats were subjected to a euglycemic-hyperinsulinemic clamp. Hyperinsulinemia (plasma values at the end of the clamp: 124 ± 18 vs. 0.5 ± 0.3 nmol/l in saline-infused rats, P<0.001) did not affect LPL activity in either epididymal (1259 ± 254 µU/g protein in saline-infused vs. 1281 ± 202 in insulin-infused rats) and perirenal (1114 ± 183 vs. 1054 ± 139) white adipose depots or in gastrocnemius muscle (8.2 ± 0.8 vs. 9.4 ± 1.0) of LPS-treated rats. Therefore, LPS-induced alterations in adipose and muscle LPL activity were independent from those in one of its major endocrine modulators.
Study 2: genetic invalidation of iNOS
As was the case in normal rats, LPS injection to wild-type mice resulted in a large increase in plasma TG concentration (from 0.8 to 1.3 mmol/l, P<0.05, Fig. 3A) . In contrast, LPS failed to induce hypertriglyceridemia in iNOS knockout mice. Compared with wild-type animals, untreated iNOS knockout mice had higher plasma levels of glucose (Table 2 ; P=0.001), probably because of a larger food intake (data not shown). However, iNOS knockout mice displayed similar plasma insulin and corticosterone concentrations. LPS injection decreased glycemia (P=0.002) and increased insulinemia (P=0.0006) and corticosterone levels (P<0.0001) in both groups of mice. Whereas plasma NEFA concentration increased by about 45% after LPS treatment in wild-type mice, it remained unchanged in knockout animals (LPS-genotype interaction: P=0.005). A strong genotype-LPS interaction was observed in the increase in plasma NO 3 /NO 2 levels (P<0.0001), which reflected the inability of iNOS knockout mice to overproduce NO during endotoxemia.
LPS administration to wild-type mice resulted in hypertriglyceridemia, which did not occur in the LPS-treated iNOS knockout mice. (Fig. 3A) . LPS administration reduced LPL activity in the gastrocnemius muscle and epididymal WAT (Fig. 3B) , as well as in the vastus lateralis muscle and perirenal WAT (not shown). Targeted disruption of the iNOS gene prevented the LPSinduced decrease in LPL activity in the gastrocnemius muscle, whereas LPS decreased LPL activity in epididymal WAT (-78%) in both wild-type and iNOS knockout mice.
DISCUSSION
Hypertriglyceridemia is among the major changes in lipid metabolism that occur during endotoxemia. This process occurs as part of the host defense (27) , as it serves to neutralize endotoxins, which can bind to circulating lipoproteins (28) , thereby lowering the endotoxininduced production of cytokines and controlling the inflammatory response (2). The increase in circulating TG levels during endotoxemia can be the result of both higher hepatic secretion (5) and lower peripheral clearance (7) . As the dose of endotoxin increases, the contribution of hepatic TG secretion to hypertriglyceridemia decreases and that of TG clearance becomes more important (8) . In rats, a dose of 0.5 mg/kg was shown to induce hypertriglyceridemia without affecting hepatic TG secretion (8) . The results obtained herein demonstrate that LPS at a dose of 15 mg/kg decreased the rate of TG secretion while giving rise to hypertriglyceridemia, which was therefore entirely due to impaired intravascular TG hydrolysis.
Lipoprotein lipase is a key enzyme in the intravascular clearance of circulating TG. The modulation of the enzyme is usually tissue-specific and reciprocal in adipose tissue and muscle (29) . For instance, after a meal, adipose tissue LPL activity is increased and muscle LPL activity is reduced (29, 30) . We have shown recently that insulin is a sufficient and necessary causal factor for the postprandial changes in LPL activity in both adipose tissue and muscle (20) . The postprandial modulation of LPL by insulin is also dependent on the duration of previous fasting, and can be counteracted by the sympathoadrenal system (31), but again in a tissue-specific, opposite manner. Therefore, endotoxemia constitutes a rare instance, along with untreated type 1 diabetes, in which LPL activity is decreased in almost every tissue (9) , thereby causing a reduction in the overall capacity for TG hydrolysis within the vascular compartment (8) .
Endotoxemia is known to alter lipoprotein composition (4, 32) , which may affect the rate at which their constituent lipids are metabolized. Bennett et al. (32) have shown that low-dose LPS resulted in the hepatic production of VLDL that were more readily taken up and oxidized by the isolated perfused rat heart. Whether this finding could be attributable to compositional changes in VLDL or to cardiac LPL has not been determined. It is unlikely that such increased tissue uptake extends to other organs such as adipose tissue and muscle (32) because it would defeat the purpose of the fall in LPL activity. Also, it is not known whether VLDL composition was altered in our experimental conditions (short-term, high dose of LPS) under which VLDL secretion was not increased but rather decreased by LPS. In any case, had LPS altered VLDL composition so as to increase its efficacy for tissue uptake, as in the study of Bennett et al. (32) , this effect would have tended to dampen LPS-induced hypertriglyceridemia and therefore reinforce the role of muscle LPL activity in producing such dyslipidemia. It remains possible that short-term, high-dose LPS may have altered VLDL composition so as to render them lessrather than more-susceptible to tissue uptake, but such an alteration would have tended to be neutralized by the lower rate of VLDL secretion. Therefore, it can reasonably be assumed that, in the present conditions, tissue LPL activity was the major modulator of triglyceridemia.
Two recent studies have reported that the reduction in LPL activity in brown adipocytes exposed to TNF-α for 24 h was mediated by overproduction of NO (18, 19) . The present findings demonstrate for the first time that, in LPS-treated rats, the decrease in muscle LPL activity is mediated by overproduction of NO via iNOS stimulation. It could be argued that because the specificity of the iNOS inhibitor AGN is not absolute, its effect on LPL may have been partly iNOS-independent. However, the pharmacological abrogation of the LPS-induced decrease in muscle LPL was confirmed in mice with genetic invalidation of iNOS, which strongly supports an iNOS-mediated action of AGN. It should be noted that the effects of NO on LPL were observed in several skeletal muscles, including the gastrocnemius, soleus, tibialis, and vastus lateralis. Therefore, the effects of NO on muscle LPL appear to be generalized and not specific to muscle fiber type. It is also important to note that AGN abrogated the LPS-induced reduction in muscle LPL activity while inhibiting LPS-induced NO overproduction by only half, as reflected by plasma NO 3 /NO 2 levels. This finding is consistent with previous studies, which have clearly shown that iNOS-mediated NO production does not have to be completely abolished to counteract NO-induced effects (33, 34) . Finally, quantitation of LPL mRNA indicated that the reduction in LPL activity was caused by posttranscriptional mechanisms, as previously suggested (10).
In WAT, it is clear from the present results that the LPS-induced reduction in LPL activity was not related to iNOS-mediated NO production. Indeed, AGN failed to prevent the decrease in LPL in all depots studied. In addition, LPL activity of LPS-treated iNOS knockout mice was half that of saline-injected animals, which further demonstrated that iNOS-mediated NO production is not implicated in the LPS-induced reduction in adipose LPL. As in the case of muscle, the lack of change in LPL mRNA in response to LPS points to posttranscriptional mechanisms of action. Regarding insulin, LPS may alter the dimerization of the enzyme or its capacity to be secreted in its active form by the adipocyte (35) . On the other hand, the present findings suggest that its contribution to the LPS-induced reduction in WAT LPL activity can be ruled out. Insulin levels in rats were decreased 6 h after LPS injection but were increased in mice. Because both species displayed a similar response of adipose LPL activity to LPS, it is unlikely that insulin participated in the LPS-induced alteration in LPL activity. The findings in LPS-treated rats infused with insulin further suggest that, in WAT, the hormone is not involved in the modulation of LPL during acute endotoxemia. However, insulin has been shown to stimulate LPL activity and synthesis in adipocytes from septic rats after 20 h of incubation (36) . Thus, insulin might in the long-term counteract the effects of LPS on adipose LPL by enhancing enzyme synthesis, possibly through stimulation of peroxisome proliferator-activated receptor -ZKLFKIDYRUs LPL gene expression (37) .
The present findings show that skeletal muscle LPL is an important determinant of triglyceridemia during high-dose endotoxemia. Indeed, in both animal models of iNOS invalidation, only muscle LPL was correlated with TG levels. Adipose tissue LPL did not appear to play a role in the process because hypertriglyceridemia was reversed by iNOS inhibition, although adipose LPL remained unchanged. Previous studies in rats have also shown that an LPS-induced reduction in skeletal muscle LPL activity in absence of any change in adipose LPL was associated with a threefold elevation in plasma TG levels (7) . It can be speculated that the preponderant influence of muscle LPL over that of adipose LPL on triglyceridemia in LPStreated rats may be related to alterations in local blood flows and their consequences on lipoprotein-LPL interactions. Although skeletal muscle and WAT are the major sites of LPL production and action on lipoprotein-bound TG, other tissues, such as the heart and brown adipose tissue, contain substantial amounts of LPL (38) and may have contributed to LPSinduced hypertriglyceridemia. This condition, however, was not the case, because iNOS inhibition prevented hypertriglyceridemia without affecting heart LPL and because brown adipose LPL was modulated in an opposite manner in mice and rats by LPS (data not shown).
The present studies therefore demonstrate that hypertriglyceridemia induced by high-dose LPS is mediated by NO through its action on skeletal muscle LPL.
It has been shown previously in vivo that the effects of endotoxins on LPL are mediated by cytokines, because no decrease in tissue LPL activity is seen in mice (C3H/HeJ) of which macrophages do not produce cytokines in response to LPS (3, 39) . Among others, TNF-α is an important factor in the reduction in LPL activity, at least in WAT (3, 40) ; whereas in skeletal muscle, interleukin-1 and interferon-γ appear to be more potent for the down-modulation of LPL in vivo (3) . The molecular mechanisms responsible for the acute, generalized reduction in LPL activity after LPS administration remain unclear. The lack of short-term changes in LPL mRNA observed here and in several previous studies using various cell and animal models (6, (10) (11) (12) indicate that LPL is altered in the short term at posttranscriptional levels. Furthermore, total immunoreactive mass of LPL appears to be conserved for an extended period after LPS exposure (6, 10) , which suggests posttranslational modes of action. Preliminary studies also suggest such a lack of change in muscle and WAT LPL mass in the present experimental conditions (F. Picard, A. Marette, Y. Deshaies, unpublished observations). It can be argued that, because LPL exists in both inactive monomeric and active homodimeric forms, LPS may decrease the ratio of the dimeric to monomeric forms of the enzyme by affecting the covalent binding between the monomers. In this regard, changes in the intracellular oxidation status brought about by NOinduced production of reactive oxygen species (41), may conceivably have an impact on the LPL dimerization process. Alternatively, increased NO production results in the nitrosation of various proteins (42) , perhaps including LPL, which may interfere with their biological activity. Finally, the effect of LPS and/or cytokines on protein degradation (43) may also extend to that of LPL.
The tissue-specificity of the involvement of NO in the LPS-induced fall in LPL activity, which has also been reported for glucose transport (44) , also remains to be explained. One possibility is that NO interacts more readily with reactive oxygen species (ROS) in muscle cells, which generate higher levels of ROS than other cell types (45) . NO may react with superoxide to form the potent oxidant peroxynitrite, which has been shown to mediate some NO effects in various tissues, including vascular, cardiac, and skeletal muscles (46, 47) . The tissue-specific nature of the involvement of NO in LPL modulation is not inconsistent with that of other modulators such as insulin and catecholamines, which each exert opposite actions on adipose and muscle LPL. Further studies are clearly needed to unravel the iNOS-independent mode of action of LPS on LPL activity in tissues such as WAT, as well as the means by which iNOS-mediated NO production reduces LPL activity in skeletal muscle. It will be particularly relevant to determine whether and how LPS and various cytokine combinations exert direct NO-dependent effects on muscle LPL in isolated whole muscle preparations and myocyte cultures. In addition, endotoxemia exerts long-term actions on TG metabolism and LPL modulation that likely involve multifaceted mechanisms, and the contribution of iNOS-mediated NO production to such longterm modulation remains to be investigated.
In conclusion, the present studies show that the LPS-induced reduction in skeletal muscle LPL activity is posttranscriptionally mediated by iNOS-induced NO production. They also demonstrate that adipose tissue LPL activity is reduced during endotoxemia by mechanisms other than iNOS-induced NO production and that do not involve changes in insulinemia. Finally, the present findings demonstrate that NO is a key factor in the LPS-mediated increase in plasma TG concentration through its modulation of LPL activity in skeletal muscle.
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